Metagenomi (MGX) Projected to Release Quarterly Earnings on Tuesday

Metagenomi (NASDAQ:MGX) will likely be releasing its Q3 2026 resultson Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.6395) per share and revenue of $2.58 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.18). The firm had revenue of ($0.26) million for the quarter, compared to the consensus estimate of $3.01 million. Metagenomi had a negative return on equity of 63.65% and a negative net margin of 384.61%. On average, analysts expect Metagenomi to post ($2.50) EPS for the current fiscal year and ($1.76) EPS for the next fiscal year.

Metagenomi Stock Performance

Metagenomi stock traded up $0.03 during trading hours on Tuesday, hitting $0.78. 19,982 shares of the stock were exchanged, compared to its average volume of 192,394. The stock has a market capitalization of $29.47 million, a P/E ratio of -0.32 and a beta of 0.69. The business’s 50-day moving average is $1.03 and its two-hundred day moving average is $1.29. Metagenomi has a 12 month low of $0.72 and a 12 month high of $2.42.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MGX. Weiss Ratings downgraded Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 22nd. Chardan Capital began coverage on Metagenomi in a research report on Tuesday, July 7th. They set a “buy” rating and a $5.00 price target on the stock. Wells Fargo & Company cut their price objective on Metagenomi to $7.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded Metagenomi from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.00.

Metagenomi Company Profile

Metagenomi, Inc is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools.

Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction.